Vanderbilt Institute for Clinical and Translational Research (VICTR)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UL1TR002243-04S2

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $96,461
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Gordon R Bernard
  • Research Location

    United States of America
  • Lead Research Institution

    Vanderbilt University Medical Center
  • Research Priority Alignment

    N/A
  • Research Category

    13

  • Research Subcategory

    N/A

  • Special Interest Tags

    Data Management and Data Sharing

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functionaland integrated clinical and translational (C&T) research infrastructure that has raised the qualityand scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry,the nation's oldest historically black academic health science institution. VICTR will contribute tothe mission of the CTSA program while leveraging unique resources and expertise withinVICTR's Hub with these aims: 1) Leverage VICTR's strong collaborative energy to enhanceteam science methodologies that propel transdisciplinary research approaches, and integrateproven community engagement principles to stakeholders for all stages of research; 2) Develop,implement and disseminate informatics and data organization methods to promulgate researchefficiency, quality, and preparedness and integrate data collection in the conduct of pragmatictrials; 3) Ensure the translational science workforce is diverse and has the skills, knowledge,and resources necessary to advance translation of discoveries; 4) Measurably improve theefficiency, quality, and representativeness of C&T studies by enhancing and systematicallyintegrating services and programs that support highest quality research initiation and conduct;5) Measurably improve the efficiency and quality of multi-site clinical trials, in collaboration withthe TICs and RICs, by leveraging centralized regulatory and legal agreements, providing rapidfeasibility and recruitment methods and practices, and creating and disseminating novel clinicaltrial designs and methodologies; and 6) Utilize unique strengths leveraging novel resourcesBioVU and PheWAS to guide drug development and repurposing.